Skip to main content

Table 1 Characteristics and evolution of acromegalic and control patients (absolute values and percentages)

From: Acromegaly and thyroid cancer: analysis of evolution in a series of patients

Patients Acro
(n = 23)
Controls
(n = 92)
p-value
Gender
[Female: n (%)]
18 (78.3) 82 (89.1) 0.29
Mean age at DTC diagnosis
(years ± SD)
49.3 ± 13.9 47.5 ± 16.5 0.31
Insulin resistance
[n (%)]
9 (39.1) 10 (10.9) 0.003
History of other cancer
[n (%)]
2 (8.7) 3 (3.3) 0.56
Histologya
[n (%)]
 clPTC 16 (69.6) 73 (79.3) 0.43
 fvPTC 7 (30.4) 19 (20.7)
Mean tumor size
[mm, (range)]
15.2 (4–35) 14.6 (3–60) 0.76
Lymphadenectomy [n (%)] 8 (34.8) 15 (16.3) 0.09
Node metastases [n (%)] 5 (62.5) 10 (66.7) 1
Radioiodine ablation [n (%)] 21 (91.3) 63 (68.5) 0.052
Median iodine dose [mCi, (range)] 100 (30–300) 100 (30–150) 0.53
Median time of follow-up
[months, (range)]
36.5 (6–120) 49.5 (6–219) 0.14
Follow-up responseb
[n (%)]
NED 19 (82.7) 60 (65.2) 0.36
Ind 2 (8.7) 22 (23.9)
BI 1 (4.3) 3 (3.3)
SI 1 (4.3) 7 (7.6)
  1. aHistology: clPTC classic papillary thyroid carcinoma. fvPTC follicular variant papillary thyroid carcinoma
  2. bFollow-up response: NED no evidence of disease, Ind indeterminate, BI biochemical incomplete, SI structural incomplete